FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase
BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular t...
Saved in:
Published in: | British journal of pharmacology Vol. 166; no. 4; pp. 1411 - 1418 |
---|---|
Main Authors: | , , |
Format: | Journal Article |
Language: | English |
Published: |
Oxford, UK
Blackwell Publishing Ltd
01-06-2012
Nature Publishing Group |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensive rats via this mechanism.
EXPERIMENTAL APPROACH The contractile and BP modulating effects of FTY720 were studied in vivo and ex vivo (wire myography) in age‐matched normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs).
KEY RESULTS Oral administration of FTY720 induced an increase in mean arterial pressure in SHR, whereas a decrease in BP was observed in WKY rats, as measured 24 h after administration. Similar to the sphingosine kinase inhibitor dimethylsphingosine (DMS), FTY720 induced large contractions in isolated carotid arteries from SHR, but not in those from WKY. In contrast, the phosphorylated form of FTY720 did not induce contractions in isolated carotid arteries from SHR. FTY720‐induced contractions were inhibited by endothelium denudation, COX and thromboxane synthase inhibitors, and by thromboxane receptor antagonism, indicating that (like DMS‐induced contractions) they were endothelium‐dependent and mediated by thromboxane A2.
CONCLUSIONS AND IMPLICATIONS These data demonstrate that FTY720 increases vascular tone and BP only in hypertensive rats, most likely as a result of its inhibitory effect on sphingosine kinase. |
---|---|
AbstractList | BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensive rats via this mechanism. EXPERIMENTAL APPROACH The contractile and BP modulating effects of FTY720 were studied in vivo and ex vivo (wire myography) in age-matched normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs). KEY RESULTS Oral administration of FTY720 induced an increase in mean arterial pressure in SHR, whereas a decrease in BP was observed in WKY rats, as measured 24 h after administration. Similar to the sphingosine kinase inhibitor dimethylsphingosine (DMS), FTY720 induced large contractions in isolated carotid arteries from SHR, but not in those from WKY. In contrast, the phosphorylated form of FTY720 did not induce contractions in isolated carotid arteries from SHR. FTY720-induced contractions were inhibited by endothelium denudation, COX and thromboxane synthase inhibitors, and by thromboxane receptor antagonism, indicating that (like DMS-induced contractions) they were endothelium-dependent and mediated by thromboxane A2. CONCLUSIONS AND IMPLICATIONS These data demonstrate that FTY720 increases vascular tone and BP only in hypertensive rats, most likely as a result of its inhibitory effect on sphingosine kinase. [PUBLICATION ABSTRACT] BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensive rats via this mechanism. EXPERIMENTAL APPROACH The contractile and BP modulating effects of FTY720 were studied in vivo and ex vivo (wire myography) in age‐matched normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs). KEY RESULTS Oral administration of FTY720 induced an increase in mean arterial pressure in SHR, whereas a decrease in BP was observed in WKY rats, as measured 24 h after administration. Similar to the sphingosine kinase inhibitor dimethylsphingosine (DMS), FTY720 induced large contractions in isolated carotid arteries from SHR, but not in those from WKY. In contrast, the phosphorylated form of FTY720 did not induce contractions in isolated carotid arteries from SHR. FTY720‐induced contractions were inhibited by endothelium denudation, COX and thromboxane synthase inhibitors, and by thromboxane receptor antagonism, indicating that (like DMS‐induced contractions) they were endothelium‐dependent and mediated by thromboxane A2. CONCLUSIONS AND IMPLICATIONS These data demonstrate that FTY720 increases vascular tone and BP only in hypertensive rats, most likely as a result of its inhibitory effect on sphingosine kinase. FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensive rats via this mechanism. The contractile and BP modulating effects of FTY720 were studied in vivo and ex vivo (wire myography) in age-matched normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs). Oral administration of FTY720 induced an increase in mean arterial pressure in SHR, whereas a decrease in BP was observed in WKY rats, as measured 24 h after administration. Similar to the sphingosine kinase inhibitor dimethylsphingosine (DMS), FTY720 induced large contractions in isolated carotid arteries from SHR, but not in those from WKY. In contrast, the phosphorylated form of FTY720 did not induce contractions in isolated carotid arteries from SHR. FTY720-induced contractions were inhibited by endothelium denudation, COX and thromboxane synthase inhibitors, and by thromboxane receptor antagonism, indicating that (like DMS-induced contractions) they were endothelium-dependent and mediated by thromboxane A₂. These data demonstrate that FTY720 increases vascular tone and BP only in hypertensive rats, most likely as a result of its inhibitory effect on sphingosine kinase. BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensive rats via this mechanism. EXPERIMENTAL APPROACH The contractile and BP modulating effects of FTY720 were studied in vivo and ex vivo (wire myography) in age‐matched normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs). KEY RESULTS Oral administration of FTY720 induced an increase in mean arterial pressure in SHR, whereas a decrease in BP was observed in WKY rats, as measured 24 h after administration. Similar to the sphingosine kinase inhibitor dimethylsphingosine (DMS), FTY720 induced large contractions in isolated carotid arteries from SHR, but not in those from WKY. In contrast, the phosphorylated form of FTY720 did not induce contractions in isolated carotid arteries from SHR. FTY720‐induced contractions were inhibited by endothelium denudation, COX and thromboxane synthase inhibitors, and by thromboxane receptor antagonism, indicating that (like DMS‐induced contractions) they were endothelium‐dependent and mediated by thromboxane A 2 . CONCLUSIONS AND IMPLICATIONS These data demonstrate that FTY720 increases vascular tone and BP only in hypertensive rats, most likely as a result of its inhibitory effect on sphingosine kinase. |
Author | Peters, Stephan LM Spijkers, Léon JA Alewijnse, Astrid E |
Author_xml | – sequence: 1 givenname: Léon JA surname: Spijkers fullname: Spijkers, Léon JA – sequence: 2 givenname: Astrid E surname: Alewijnse fullname: Alewijnse, Astrid E – sequence: 3 givenname: Stephan LM surname: Peters fullname: Peters, Stephan LM |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25934376$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22251137$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc1u1DAUhS3Uik4Lr4AsIaSySPBv4ixAohVtkSrBoixYWY5jdzxk7NROhs4L8Nw4zDDADi9sS_e75xzpnIIjH7wBAGJU4nzerErM6qrgVOCSIExKhEXFy8cnYHEYHIEFQqguMBbiBJymtEIoD2v-FJwQQjjGtF6AH1d3X2uC4Ll1_j70bh2619B5HY1KJsGNSnrqVYRjDgCV72Dbh9DBIZqUpmgyCtMQ_Ki8CVPqt3C5HUwcjU9uY2BUY9ZwKmNL17rRBQ-DzRvL2S25rPnN-ez0DBxb1SfzfP-egS9XH-4ub4rbT9cfL9_fFpo3ghdWM8sEYZWmCDUdEqyhqGOYtMpaq7t8K8NpY1pViY6yrjG1tkoLIypCsaVn4N1Od5jatem08WNUvRyiW6u4lUE5-e_Eu6W8DxtJGa4Zr7LAy71ADA-TSaNchSn6nFliznjNCUI8U2JH6RhSisYeHDCSc4NyJeei5FyUnBuUvxqUj3n1xd8JD4u_K8vAqz2Qu1G9jcprl_5wvKGM1nPStzvuu-vN9r8DyIvPN_OP_gRclr0R |
CODEN | BJPCBM |
CitedBy_id | crossref_primary_10_1093_biolre_ioab012 crossref_primary_10_1371_journal_pone_0162029 crossref_primary_10_1016_j_jaut_2016_03_012 crossref_primary_10_1111_nmo_13372 crossref_primary_10_1016_j_ejphar_2018_10_027 crossref_primary_10_1161_HYPERTENSIONAHA_117_09088 crossref_primary_10_1371_journal_pone_0097196 crossref_primary_10_1007_s13760_017_0794_7 crossref_primary_10_1016_j_dld_2024_03_010 crossref_primary_10_1124_jpet_116_236208 crossref_primary_10_1111_bph_14381 crossref_primary_10_1124_jpet_116_233205 crossref_primary_10_1111_wrr_12685 crossref_primary_10_2174_1871527319666200825164123 crossref_primary_10_3389_fcvm_2022_915961 crossref_primary_10_1016_j_phrs_2020_104793 crossref_primary_10_1161_HYPERTENSIONAHA_117_10655 |
Cites_doi | 10.1212/WNL.0b013e3181e3972b 10.1111/j.1476-5381.2009.00451.x 10.1152/ajpheart.01089.2002 10.1124/dmd.110.035907 10.1016/j.phrs.2010.09.002 10.1111/j.1476-5381.2011.01260.x 10.1056/NEJMoa0907839 10.1016/j.ejphar.2008.02.089 10.1161/01.RES.41.1.19 10.1042/BST0350908 10.1002/bdd.535 10.1007/s10059-010-0042-y 10.1038/sj.bjp.0707581 10.1182/blood-2006-03-011437 10.1111/j.1476-5381.2011.01649_1.x 10.1074/jbc.M805186200 10.1038/nrc2875 10.1007/s10059-010-0041-z 10.1161/01.RES.0000164321.91452.00 10.1084/jem.20091343 10.1007/s00395-008-0744-x 10.5414/CPP45098 10.1056/NEJMoa0909494 10.1371/journal.pone.0029222 10.1002/jbt.20193 10.1177/1352458509357065 10.1074/jbc.M307687200 10.1177/0091270006289853 10.1016/j.cellsig.2010.05.022 10.1371/journal.pone.0021817 10.1021/jm050242f 10.1038/nrm2329 10.1124/jpet.103.062828 |
ContentType | Journal Article |
Copyright | 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society 2015 INIST-CNRS 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society. 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society 2012 |
Copyright_xml | – notice: 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society – notice: 2015 INIST-CNRS – notice: 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society. – notice: 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society 2012 |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7TK K9. NAPCQ 5PM |
DOI | 10.1111/j.1476-5381.2012.01865.x |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Calcium & Calcified Tissue Abstracts Neurosciences Abstracts |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1476-5381 |
EndPage | 1418 |
ExternalDocumentID | 3376261041 10_1111_j_1476_5381_2012_01865_x 22251137 25934376 BPH1865 |
Genre | article Journal Article |
GroupedDBID | --- .3N .55 .GJ 05W 0R~ 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 3V. 4.4 52U 52V 53G 5GY 6J9 7RV 7X7 8-0 8-1 88E 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 8UM A00 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCUV ABDBF ABPVW ABQWH ABUWG ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFKRA AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB B0M BAFTC BAWUL BBNVY BENPR BFHJK BHBCM BHPHI BKEYQ BMXJE BPHCQ BRXPI BVXVI C45 CAG CCPQU COF CS3 DCZOG DIK DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EAS EBC EBD EBS ECV EJD EMB EMK EMOBN ENC ESX EX3 F5P FUBAC FYUFA G-S GODZA GX1 H.X HCIFZ HGLYW HMCUK HYE HZ~ J5H KBYEO LATKE LEEKS LH4 LITHE LK8 LOXES LSO LUTES LW6 LYRES M1P M7P MEWTI MK0 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N9A NAPCQ NF~ O66 O9- OIG OK1 OVD P2P P2W P4E PQQKQ PROAC PSQYO Q.N Q2X QB0 RIG ROL RPM RWI SJN SUPJJ SV3 TEORI TR2 TUS UKHRP UPT WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WVDHM WXSBR X7M XV2 Y6R YHG ZGI ZXP ZZTAW ~8M ~S- 08R AAJUZ AAPBV AAUGY AAVGM ABCVL ABHUG ABPTK ABWRO ACXME ADAWD ADDAD AFVGU AGJLS IQODW ZA5 CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7TK K9. 5PM |
ID | FETCH-LOGICAL-c5985-fc4f48246c3009d084930d412bafffcdaffae539eba68d34d9e7cfac8e86231f3 |
IEDL.DBID | RPM |
ISSN | 0007-1188 |
IngestDate | Tue Sep 17 21:08:56 EDT 2024 Thu Oct 10 19:52:24 EDT 2024 Fri Aug 23 00:36:31 EDT 2024 Sat Sep 28 07:59:41 EDT 2024 Sun Oct 22 16:07:41 EDT 2023 Sat Aug 24 00:44:46 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Rat sphingolipids sphingosine kinase Cardiovascular disease Vasomotricity Sphingosine Arterial pressure Blood pressure Hypertension EDCF Fingolimod Enzyme Transferases Rodentia Vasoconstriction Sphingolipid Endothelium Immunomodulator Vertebrata Mammalia Kinase Animal FTY720 Hemodynamics Immunosuppressive agent |
Language | English |
License | CC BY 4.0 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5985-fc4f48246c3009d084930d412bafffcdaffae539eba68d34d9e7cfac8e86231f3 |
OpenAccessLink | https://europepmc.org/articles/pmc3417456?pdf=render |
PMID | 22251137 |
PQID | 1545752005 |
PQPubID | 42104 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3417456 proquest_journals_1545752005 crossref_primary_10_1111_j_1476_5381_2012_01865_x pubmed_primary_22251137 pascalfrancis_primary_25934376 wiley_primary_10_1111_j_1476_5381_2012_01865_x_BPH1865 |
PublicationCentury | 2000 |
PublicationDate | June 2012 |
PublicationDateYYYYMMDD | 2012-06-01 |
PublicationDate_xml | – month: 06 year: 2012 text: June 2012 |
PublicationDecade | 2010 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Basingstoke – name: England – name: London |
PublicationTitle | British journal of pharmacology |
PublicationTitleAlternate | Br J Pharmacol |
PublicationYear | 2012 |
Publisher | Blackwell Publishing Ltd Nature Publishing Group |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Nature Publishing Group |
References | 2010; 10 2010; 16 2010; 207 2007a; 28 2011a; 6 2008; 9 2010; 362 1977; 41 2008; 1 2005; 48 2008; 585 2011; 39 2003; 278 2007; 109 2009; 158 2007; 35 2010; 62 2004; 309 2007b; 45 2010; 22 2006; 46 2010; 29 2011b; 6 2005; 96 2009; 284 2011; 163 2007; 21 2008; 153 2010; 74 2009; 104 2011; 164 2003; 284 17323789 - Int J Clin Pharmacol Ther. 2007 Feb;45(2):98-109 18026125 - Br J Pharmacol. 2008 Jan;153(1):140-7 21309759 - Br J Pharmacol. 2011 Jul;163(6):1140-62 20127284 - Mol Cells. 2010 Feb 28;29(2):105-11 14747617 - J Pharmacol Exp Ther. 2004 May;309(2):758-68 21818267 - PLoS One. 2011;6(7):e21817 18777003 - Basic Res Cardiol. 2009 Jan;104(1):50-9 13129923 - J Biol Chem. 2003 Nov 28;278(48):47408-15 862138 - Circ Res. 1977 Jul;41(1):19-26 20555359 - Nat Rev Cancer. 2010 Jul;10(7):489-503 16078855 - J Med Chem. 2005 Aug 11;48(16):5373-7 16855074 - J Clin Pharmacol. 2006 Aug;46(8):895-904 19812733 - Perspect Medicin Chem. 2007 Sep 06;1:11-23 21045200 - Drug Metab Dispos. 2011 Feb;39(2):199-207 22195025 - PLoS One. 2011;6(12):e29222 12742827 - Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H2045-52 20584883 - J Exp Med. 2010 Jul 5;207(7):1475-83 22040146 - Br J Pharmacol. 2011 Nov;164 Suppl 1:S1-324 20548047 - Neurology. 2010 Jun 15;74(24):2022-4 20028707 - Mult Scler. 2010 Feb;16(2):197-207 20127285 - Mol Cells. 2010 Feb 28;29(2):99-104 18420192 - Eur J Pharmacol. 2008 May 13;585(2-3):292-302 17956243 - Biochem Soc Trans. 2007 Nov;35(Pt 5):908-9 18216770 - Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50 20089952 - N Engl J Med. 2010 Feb 4;362(5):387-401 15802614 - Circ Res. 2005 Apr 29;96(8):913-20 17008548 - Blood. 2007 Feb 1;109(3):1077-85 17912702 - J Biochem Mol Toxicol. 2007;21(5):273-9 17230596 - Biopharm Drug Dispos. 2007 Mar;28(2):97-104 19119142 - J Biol Chem. 2009 Feb 27;284(9):5467-77 20089954 - N Engl J Med. 2010 Feb 4;362(5):402-15 20850539 - Pharmacol Res. 2010 Dec;62(6):465-74 19814729 - Br J Pharmacol. 2009 Nov;158(5):1173-82 20570726 - Cell Signal. 2010 Oct;22(10):1536-42 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_16_1 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_11_1 e_1_2_8_34_1 Adachi K (e_1_2_8_2_1) 2008; 1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_30_1 |
References_xml | – volume: 362 start-page: 402 year: 2010 end-page: 415 article-title: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis publication-title: N Engl J Med – volume: 1 start-page: 11 year: 2008 end-page: 23 article-title: FTY720 story. Its discovery and the following accelerated development of sphingosine 1‐phosphate receptor agonists as immunomodulators based on reverse pharmacology publication-title: Perspect Med Chem – volume: 278 start-page: 47408 year: 2003 end-page: 47415 article-title: Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases publication-title: J Biol Chem – volume: 45 start-page: 98 year: 2007b end-page: 109 article-title: Ethnic sensitivity study of fingolimod in White and Asian subjects publication-title: Int J Clin Pharmacol Ther – volume: 6 start-page: e29222 year: 2011b article-title: Antihypertensive treatment differentially affects vascular sphingolipid biology in spontaneously hypertensive rats publication-title: PLoS One – volume: 48 start-page: 5373 year: 2005 end-page: 5377 article-title: Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer publication-title: J Med Chem – volume: 41 start-page: 19 year: 1977 end-page: 26 article-title: Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats publication-title: Circ Res – volume: 585 start-page: 292 year: 2008 end-page: 302 article-title: Sphingolipid signalling in the cardiovascular system: good, bad or both? publication-title: Eur J Pharmacol – volume: 109 start-page: 1077 year: 2007 end-page: 1085 article-title: The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A independently of sphingosine‐1‐phosphate receptors publication-title: Blood – volume: 153 start-page: 140 year: 2008 end-page: 147 article-title: Analysis of sphingosine 1‐phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools publication-title: Br J Pharmacol – volume: 35 start-page: 908 year: 2007 end-page: 909 article-title: The potential roles of sphingolipids in vascular smooth‐muscle function publication-title: Biochem Soc Trans – volume: 16 start-page: 197 year: 2010 end-page: 207 article-title: Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results publication-title: Mult Scler – volume: 10 start-page: 489 year: 2010 end-page: 503 article-title: Sphingosine 1‐phosphate and cancer publication-title: Nat Rev Cancer – volume: 9 start-page: 139 year: 2008 end-page: 150 article-title: Principles of bioactive lipid signalling: lessons from sphingolipids publication-title: Nat Rev Mol Cell Biol – volume: 163 start-page: 1140 year: 2011 end-page: 1162 article-title: Pharmacological relevance and potential of sphingosine 1‐phosphate in the vascular system publication-title: Br J Pharmacol – volume: 284 start-page: 5467 year: 2009 end-page: 5477 article-title: FTY720 inhibits ceramide synthases and up‐regulates dihydrosphingosine 1‐phosphate formation in human lung endothelial cells publication-title: J Biol Chem – volume: 207 start-page: 1475 year: 2010 end-page: 1483 article-title: Cell‐surface residence of sphingosine 1‐phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics publication-title: J Exp Med – volume: 164 start-page: S1 issue: 1 year: 2011 end-page: S324 article-title: Guide to Receptors and Channels (GRAC), 5th Edition publication-title: Br J Pharmacol – volume: 309 start-page: 758 year: 2004 end-page: 768 article-title: Immune cell regulation and cardiovascular effects of sphingosine 1‐phosphate receptor agonists in rodents are mediated via distinct receptor subtypes publication-title: J Pharmacol Exp Ther – volume: 62 start-page: 465 year: 2010 end-page: 474 article-title: Vessel‐specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries publication-title: Pharmacol Res – volume: 96 start-page: 913 year: 2005 end-page: 920 article-title: Immunomodulator FTY720 induces eNOS‐dependent arterial vasodilatation via the lysophospholipid receptor S1P publication-title: Circ Res – volume: 28 start-page: 97 year: 2007a end-page: 104 article-title: Oral‐intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects publication-title: Biopharm Drug Dispos – volume: 104 start-page: 50 year: 2009 end-page: 59 article-title: Activation of sphingosine kinase by muscarinic receptors enhances NO‐mediated and attenuates EDHF‐mediated vasorelaxation publication-title: Basic Res Cardiol – volume: 39 start-page: 199 year: 2011 end-page: 207 article-title: Absorption and disposition of the sphingosine 1‐phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways publication-title: Drug Metab Dispos – volume: 158 start-page: 1173 year: 2009 end-page: 1182 article-title: FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system publication-title: Br J Pharmacol – volume: 22 start-page: 1536 year: 2010 end-page: 1542 article-title: FTY720 and (S)‐FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen‐independent prostate cancer cells publication-title: Cell Signal – volume: 362 start-page: 387 year: 2010 end-page: 401 article-title: A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis publication-title: N Engl J Med – volume: 29 start-page: 99 year: 2010 end-page: 104 article-title: Sphingosine‐1‐phosphate receptors: zooming in on ligand‐induced intracellular trafficking and its functional implications publication-title: Mol Cells – volume: 6 start-page: e21817 year: 2011a article-title: Hypertension is associated with marked alterations in sphingolipid biology: a potential role for ceramide publication-title: PLoS One – volume: 284 start-page: H2045 year: 2003 end-page: H2052 article-title: Sphingosine 1‐phosphate and control of vascular tone publication-title: Am J Physiol Heart Circ Physiol – volume: 21 start-page: 273 year: 2007 end-page: 279 article-title: Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart publication-title: J Biochem Mol Toxicol – volume: 29 start-page: 105 year: 2010 end-page: 111 article-title: Sphingolipids and the orchestration of endothelium‐derived vasoactive factors: when endothelial function demands greasing publication-title: Mol Cells – volume: 74 start-page: 2022 year: 2010 end-page: 2024 article-title: Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis publication-title: Neurology – volume: 46 start-page: 895 year: 2006 end-page: 904 article-title: FTY720: placebo‐controlled study of the effect on cardiac rate and rhythm in healthy subjects publication-title: J Clin Pharmacol – ident: e_1_2_8_26_1 doi: 10.1212/WNL.0b013e3181e3972b – ident: e_1_2_8_8_1 doi: 10.1111/j.1476-5381.2009.00451.x – ident: e_1_2_8_11_1 doi: 10.1152/ajpheart.01089.2002 – ident: e_1_2_8_35_1 doi: 10.1124/dmd.110.035907 – ident: e_1_2_8_23_1 doi: 10.1016/j.phrs.2010.09.002 – ident: e_1_2_8_25_1 doi: 10.1111/j.1476-5381.2011.01260.x – ident: e_1_2_8_9_1 doi: 10.1056/NEJMoa0907839 – ident: e_1_2_8_4_1 doi: 10.1016/j.ejphar.2008.02.089 – ident: e_1_2_8_18_1 doi: 10.1161/01.RES.41.1.19 – ident: e_1_2_8_19_1 doi: 10.1042/BST0350908 – ident: e_1_2_8_15_1 doi: 10.1002/bdd.535 – ident: e_1_2_8_27_1 doi: 10.1007/s10059-010-0042-y – ident: e_1_2_8_22_1 doi: 10.1038/sj.bjp.0707581 – ident: e_1_2_8_20_1 doi: 10.1182/blood-2006-03-011437 – volume: 1 start-page: 11 year: 2008 ident: e_1_2_8_2_1 article-title: FTY720 story. Its discovery and the following accelerated development of sphingosine 1‐phosphate receptor agonists as immunomodulators based on reverse pharmacology publication-title: Perspect Med Chem contributor: fullname: Adachi K – ident: e_1_2_8_5_1 doi: 10.1111/j.1476-5381.2011.01649_1.x – ident: e_1_2_8_6_1 doi: 10.1074/jbc.M805186200 – ident: e_1_2_8_21_1 doi: 10.1038/nrc2875 – ident: e_1_2_8_33_1 doi: 10.1007/s10059-010-0041-z – ident: e_1_2_8_31_1 doi: 10.1161/01.RES.0000164321.91452.00 – ident: e_1_2_8_30_1 doi: 10.1084/jem.20091343 – ident: e_1_2_8_17_1 doi: 10.1007/s00395-008-0744-x – ident: e_1_2_8_16_1 doi: 10.5414/CPP45098 – ident: e_1_2_8_14_1 doi: 10.1056/NEJMoa0909494 – ident: e_1_2_8_29_1 doi: 10.1371/journal.pone.0029222 – ident: e_1_2_8_34_1 doi: 10.1002/jbt.20193 – ident: e_1_2_8_10_1 doi: 10.1177/1352458509357065 – ident: e_1_2_8_7_1 doi: 10.1074/jbc.M307687200 – ident: e_1_2_8_24_1 doi: 10.1177/0091270006289853 – ident: e_1_2_8_32_1 doi: 10.1016/j.cellsig.2010.05.022 – ident: e_1_2_8_28_1 doi: 10.1371/journal.pone.0021817 – ident: e_1_2_8_3_1 doi: 10.1021/jm050242f – ident: e_1_2_8_13_1 doi: 10.1038/nrm2329 – ident: e_1_2_8_12_1 doi: 10.1124/jpet.103.062828 |
SSID | ssj0014775 |
Score | 2.2050202 |
Snippet | BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical... FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated... BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical... |
SourceID | pubmedcentral proquest crossref pubmed pascalfrancis wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1411 |
SubjectTerms | Animals Arterial hypertension. Arterial hypotension Biological and medical sciences Blood Blood and lymphatic vessels Blood Pressure - drug effects Cardiology. Vascular system Carotid Arteries - cytology Carotid Arteries - drug effects Carotid Arteries - metabolism Carotid Arteries - pathology Cyclooxygenase Inhibitors - pharmacology EDCF Endothelium Endothelium, Vascular - cytology Endothelium, Vascular - drug effects Endothelium, Vascular - metabolism Endothelium, Vascular - pathology Enzyme Inhibitors - adverse effects Enzyme Inhibitors - chemistry Enzyme Inhibitors - pharmacology Fingolimod Fingolimod Hydrochloride FTY720 hypertension Hypertension - chemically induced Hypertension - metabolism Hypertension - pathology Hypertension - physiopathology Immunosuppressive Agents - adverse effects Immunosuppressive Agents - chemistry Immunosuppressive Agents - pharmacology Isoenzymes - antagonists & inhibitors Isoenzymes - metabolism Kinases Male Medical sciences Muscle, Smooth, Vascular - cytology Muscle, Smooth, Vascular - drug effects Muscle, Smooth, Vascular - metabolism Muscle, Smooth, Vascular - pathology Pharmacology. Drug treatments Phosphorylation Phosphotransferases (Alcohol Group Acceptor) - antagonists & inhibitors Phosphotransferases (Alcohol Group Acceptor) - metabolism Propylene Glycols - adverse effects Propylene Glycols - chemistry Propylene Glycols - pharmacology Rats Rats, Inbred SHR Rats, Inbred WKY Research Papers Rodents sphingolipids Sphingosine - adverse effects Sphingosine - analogs & derivatives Sphingosine - chemistry Sphingosine - pharmacology sphingosine kinase Thromboxane A2 - antagonists & inhibitors Thromboxane A2 - metabolism Vascular Resistance - drug effects vasoconstriction Vasoconstrictor Agents - adverse effects Vasoconstrictor Agents - chemistry Vasoconstrictor Agents - pharmacology |
SummonAdditionalLinks | – databaseName: Wiley-Blackwell dbid: 33P link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LitswFL20syqUvh-eTgctytDCuNiRbMnLPiaELkqgKbQrIetBzAzOEDfQ_MB8d--V8xi3syilmxASyQ_lXOtc5dwjgFdZrlwoqjqtTOZTYSRP60yEtK7qIGmbzGCpOHnyRX7-pj6ekU3Op20tTO8PsVtwo8iIz2sKcFN3vwW5LFMMWErzaEkvV2XxlvgkJg2xmoNPd38oCCn7zQzIEzFXaijqufFAg5nq7qXpcNBCv9vFTXT0T1XldbYbp6vx_f95ow_g3oa0snc9yh7CLd8-gpNp73q9PmWzfRFXd8pO2HTvh71-DFfj2Xc5ytjrgNPk4gLB4d6wpiW62vmObbWwjGzBmWkdi2J6FhW6q6XHpox0vMhi_WLVXazZHHPn5UZ5zxDBeIzGYLN5U0cBGlsE7EFLawtS9bPzpsUzPYGv47PZh0m62f4htUWlijRYEYQaidJyJIIuU6LimRP5qDYhBOvw1fiCV742pXJcuMpLG4xVHrM0ngf-FA5avPLnwJzg0uZBhdIqmoBrRSXLBkFpkWH6PIF8-1Pry97lQ1_PjmSpafg1Db-Ow69_JnA8wMSuIyaUHM9XJnC0BYnePBg6TYxVktVVkcCzHi_7jiPK97hMQA6QtGtAVuDDb9pmHi3BkYtIpMIJlBFJf30T-v10Qu8O_7XjC7hDH_fiuSM4-LFc-Zdwu3Or4xiAvwBUVTJR priority: 102 providerName: Wiley-Blackwell |
Title | FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1476-5381.2012.01865.x https://www.ncbi.nlm.nih.gov/pubmed/22251137 https://www.proquest.com/docview/1545752005 https://pubmed.ncbi.nlm.nih.gov/PMC3417456 |
Volume | 166 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1di9NAFB3sPgkifhtdyzzIorDZZjqTzORRd7dURAlYQZ9CMh80bDctjYXtH9jf7b2TZNuiD-JLCGQmk-TeyT03OXMuIW8jpoyL0zJMi8iGopA8LCPhwjItncQymU7j4uTpN_n1h7q4RJmcuF8L40n7uqzO6sX1WV3NPbdyda1HPU9slH05hzevhMA_GpABYMM-Re9-HQgp27IFqH7IlDqk7wiZhDDHMTPEr4BMJbHXosa0hzGshr4Xnh6sigaelGtLXPwNg_5JpdyHuD5GTR6Rhx24pB_am3hM7tn6CTnJWnXq7Smd7RZbNaf0hGY73ertU3I7mf2U44i-cxDOlgswonlPqxphZWMb2nNWKcp306I21JPeqWfSbtYWmlLk2wLatMtNs9jSOeS4644hT8HT4BxVAc3mVemJYnTpoAd-Alsi-55eVTWM9Ix8n1zOzqdhV6Yh1HGq4tBp4YQai0RzAGwmUiLlkRFsXBbOOW1gW9iYp7YsEmW4MKmV2hVaWcimOHP8OTmq4cpfEmoEl5o55RKtMFCWCpcWF-A8GpCgZQFhvXXyVavGke9nMTLJ0bg5Gjf3xs1vAjI8MONdR0j8OIyXBOS4t2veTeAmR2QpUZIqDsiL1sS7jp2vBEQeGP-uAUp2Hx4BT_bS3Z3nBiTxbvLPN5F_zKa49-q_h3xN7uMJW5bbMTn6td7YN2TQmM2QDDjPYHvx6fPQz6XfEkUgeA |
link.rule.ids | 230,315,729,782,786,887,1408,27935,27936,46066,46490,53803,53805 |
linkProvider | National Library of Medicine |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFD6C8QDSxB0WGMMPaAJpQUntxM4jl1VFG1MligRPluOLGjGlU0Ml-gf43ZyT9LLAHhDipYpUO2mc78TfcT9_B-BFkioXsqKMC5P4WBjJ4zIRIS6LMkgqkxksbU4efZJnX9T7Y7LJOVnvhen8ITYLbhQZ7fuaApwWpH-LcpnHGLGU59GaXqry7DUSyhsiFwXVceB8vPlLQUjZlTMgV8RUqb6s58oz9eaq3QvT4LCFrt7FVYT0T13lZb7bTljDO__1Vu_C7RVvZW86oN2Da76-D4fjzvh6ecQm231czRE7ZOOtJfbyAfwcTr7KQcJeBpwpZ-eID_eKVTUx1sY3bC2HZeQMzkztWKunZ61IdzH32JSRlBeJrJ8tmvMlm2L6PF-J7xmCGM9RGWw2rcpWg8ZmAXvQ6tqMhP3sW1XjlR7C5-Hx5N0oXlWAiG1WqCwOVgShBiK3HLmgS5QoeOJEOihNCME6_DQ-44UvTa4cF67w0gZjlcdEjaeBP4KdGn_5HjAnuLRpUCG3iubgUtGuZYO4tEgyfRpBun7W-qIz-tCXEySZaxp-TcOv2-HXPyI46IFi0xFzSo7XyyPYX6NEr94NjSbSKsntKovgcQeYbccBpXxcRiB7UNo0IDfw_jd1NW1dwZGOSGTDEeQtlP76JvTb8YiOnvxrx-dwczT5eKpPP5ydPIVb1KTT0u3Dzvf5wj-D641bHLTR-At83jZy |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9NAFD7oCiKI90t0XedBFoXNknQmmcmjulvqhaVgBX0aJnOhwSUtjQX7B_zdnpP0stF9EPGlBDqTNJPvZL4z_c43AC-SVLmQFWVcmMTHwkgel4kIcVmUQdI2mcFScfLokzz7ok5OySbn_aYWpvOH2C64UWS072sK8LkLvwW5zGMMWErzaEkvVXl2jHzymiBWTuUcfLz9R0FI2e1mQKaIqVJ9Vc-lZ-pNVTfnpsFRC912F5fx0T9llRfpbjtfDW__zzu9A7fWrJW97mB2F674-h4cjjvb69URm-yquJojdsjGO0Ps1X34OZx8lYOEvQw4T87OER3uFatq4quNb9hGDMvIF5yZ2rFWTc9aie5y4bEpIyEv0lg_WzbnKzbF5Hmxlt4zhDCeozLYbFqVrQKNzQL2oLW1Gcn62beqxis9gM_D08nbUbze_yG2WaGyOFgRhBqI3HJkgi5RouCJE-mgNCEE6_DT-IwXvjS5cly4wksbjFUe0zSeBv4Q9mr85Y-BOcGlTYMKuVU0A5eKapYNotIixfRpBOnmUet5Z_OhL6ZHMtc0_JqGX7fDr39EcNDDxLYjZpQcr5dHsL8BiV6_GRpNlFWS11UWwaMOL7uOA0r4uIxA9pC0bUBe4P1v6mraeoIjGZHIhSPIWyT99U3oN-MRHT35147P4fr4ZKg_vjv78BRuUItOSLcPe98XS_8MrjZuedDG4i-mgjUh |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FTY720+%28fingolimod%29+increases+vascular+tone+and+blood+pressure+in+spontaneously+hypertensive+rats+via+inhibition+of+sphingosine+kinase&rft.jtitle=British+journal+of+pharmacology&rft.au=Spijkers%2C+L%C3%A9on+JA&rft.au=Alewijnse%2C+Astrid+E&rft.au=Peters%2C+Stephan+LM&rft.date=2012-06-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0007-1188&rft.eissn=1476-5381&rft.volume=166&rft.issue=4&rft.spage=1411&rft.epage=1418&rft_id=info:doi/10.1111%2Fj.1476-5381.2012.01865.x&rft.externalDBID=10.1111%252Fj.1476-5381.2012.01865.x&rft.externalDocID=BPH1865 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1188&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1188&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1188&client=summon |